HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

talniflumate

an anti-inflammatory molecule for the treatment of cystic fibrosis, chronic obstructive pulmonary disease and asthma

Networked: 7 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - talniflumate: 7
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzofurans: 26
      - talniflumate: 7

Experts

1.	Jin, Li Hua: 1 article (12/2017)
2.	Kim, Bo-Hyung: 1 article (12/2017)
3.	Kwack, KyuBum: 1 article (12/2017)
4.	Lee, Ji Hyun: 1 article (12/2017)
5.	Lee, Kidong: 1 article (12/2017)
6.	Yim, Sung-Vin: 1 article (12/2017)
7.	Biddick, Laura: 1 article (01/2016)
8.	Bryant, Taylor: 1 article (01/2016)
9.	Gali, Hariprasad: 1 article (01/2016)
10.	Janakiram, Naveena B: 1 article (01/2016)

Related Diseases

1.	Pancreatic Neoplasms (Pancreatic Cancer) 11/23/2023 - "Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment in pancreatic cancer."
2.	Cystic Fibrosis (Mucoviscidosis) 05/01/2004 - "Phase I trials with talniflumate had been completed by August 2001, and phase II trials were underway in Ireland for the treatment of cystic fibrosis." 04/01/2006 - "Talniflumate increases survival in a cystic fibrosis mouse model of distal intestinal obstructive syndrome." 05/01/2004 - "Talniflumate, an anti-inflammatory molecule that was originally developed by Laboratorios Bago, is currently being developed by Genaera as a mucoregulator for the treatment of cystic fibrosis, chronic obstructive pulmonary disease and asthma. "
3.	Carcinogenesis 01/01/2016 - "Furthermore, talniflumate alone and in combination with low-dose gefitinib reduced GCNT3 expression, leading to the disrupted production of mucins in vivo and in vitro Collectively, our findings suggest that targeting mucin biosynthesis through GCNT3 may improve drug responsiveness, warranting further development and investigation in preclinical models of pancreatic tumorigenesis. "
4.	Chronic Obstructive Pulmonary Disease (COPD) 05/01/2004 - "Talniflumate, an anti-inflammatory molecule that was originally developed by Laboratorios Bago, is currently being developed by Genaera as a mucoregulator for the treatment of cystic fibrosis, chronic obstructive pulmonary disease and asthma. "
5.	Respiratory Tract Infections (Respiratory Tract Infection) 08/01/2023 - "The GBM identified 5 medications (loxoprofen, aceclofenac, talniflumate, meloxicam, and dexibuprofen) and 2 comorbidities (acute upper respiratory tract infection [AURI] and gastroesophageal reflux disease) as important features. "

Related Drugs and Biologics

1.	Mucins
2.	Gemcitabine
3.	130-nm albumin-bound paclitaxel
4.	Chloride Channels (Chloride Channel)
5.	Niflumic Acid
6.	Esters
7.	Analgesics (Analgesic Drugs)
8.	Meloxicam (Mobic)
9.	Gefitinib (Iressa)
10.	dexibuprofen

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)